Adalimumab, Infliximab, and Etanercept Biosimilars Global Market Report 2022 by The Business Research Company is the most comprehensive report available on the market, being wide-ranging both in terms of chronology and geography. It covers the historic period – 2016-2021, and the forecast period – 2022-2026, with additional forecasts for 2026-2031. The report helps gain a truly global perspective as it covers 60 geographies, focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
TBRC’s market report includes a chapter on the COVID-19 impact on the adalimumab, infliximab, and etanercept biosimilars industry, which gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market and how companies can strategize to bounce back from it. With updated market numbers according to the effects of the coronavirus, the report provides the most accurate expected adalimumab, infliximab, and etanercept biosimilars market growth numbers from 2022-2031.
Request a Sample of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
The global adalimumab, infliximab, and etanercept biosimilars market is expected to grow from $3.10 billion in 2021 to $4.76 billion in 2022 at a compound annual growth rate (CAGR) of 53.4%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The adalimumab, infliximab and etanercept biosimilar market is expected to reach $18.61 billion in 2026 at a CAGR of 40.6%.
View more on the report:
The Adalimumab, Infliximab, and Etanercept Biosimilars Global Market Report 2022-31 by The Business Research Company evaluates adalimumab, infliximab, and etanercept biosimilars market size, growth rate, drivers, adalimumab, infliximab, and etanercept biosimilars industry trends, and major companies.
The adalimumab, infliximab, and etanercept biosimilars market segments in the report are:
1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)
2) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Others
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The table of contents in TBRC’s adalimumab, infliximab, and etanercept biosimilars market report includes:
- Executive Summary
- Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics
- Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies
- Impact Of COVID-19 On Adalimumab, Infliximab and Etanercept Biosimilars
- Adalimumab, Infliximab and Etanercept Biosimilars Market Size And Growth.
.
- Adalimumab, Infliximab and Etanercept Biosimilars Pipeline Analysis
- Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market
- Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis
- Appendix
List Of Tables
Table 1: Global Historic Market Growth, 2016-2021, $ Billion
Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
Table 3: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Table 4: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Table 5: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
.
Table 28: Sandoz (Novartis) Financial Performance
Table 29: Samsung Bioepis Financial Performance
Table 30: Abbvie Financial Performance
Table 31: Amgen Financial Performance
List Of Related Reports
Pegfilgrastim Biosimilars Market
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market
Biosimilar Therapeutic Peptides Global Market Report
Biosimilar Hormones Global Market Report
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
